Cargando…

A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape

BACKGROUND: The diversity and plasticity behind ER+/PR−/HER2− breast cancer have not been widely explored. It is essential to identify heterogeneous microenvironment phenotypes and investigate specific genomic events driving the formation of these phenotypes. METHODS: Based on the immune-related gen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Peiling, An, Rui, Yu, Shibo, He, Jianjun, Zhang, Huimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454077/ https://www.ncbi.nlm.nih.gov/pubmed/34544424 http://dx.doi.org/10.1186/s12967-021-03076-x

Ejemplares similares

Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
por: Hu, Taobo, et al.
Publicado: (2021)

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers
por: Ballot, Elise, et al.
Publicado: (2022)

Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer
por: Lundgren, Christine, et al.
Publicado: (2019)

Pituitary, Gonadal, Thyroid Hormones and Endocrine Disruptors in Pre and Postmenopausal Nigerian Women with ER-, PR- and HER-2-Positive and Negative Breast Cancers
por: Ajayi, Olulope, et al.
Publicado: (2018)

Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers
por: Parise, Carol A., et al.
Publicado: (2014)

Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report
por: Schlotman, Alyssa, et al.
Publicado: (2020)

Is oestrogen receptor-negative/progesterone receptor-positive (ER−/PR+) a real pathological entity?
por: Onitilo, Adedayo A, et al.
Publicado: (2021)

BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma
por: Kumar, Mohit, et al.
Publicado: (2017)

High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
por: Voutsadakis, Ioannis A.
Publicado: (2022)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

ODP433 An increased in AIPB expression in Triple Negative (ER-/PR-/Her2-) Breast Tumors reduces estradiol synthesis
por: Downs, William V, et al.
Publicado: (2022)

THU555 Stress Induced AIPB Expression In Triple Negative (ER-/PR-/Her2-) Breast Tumors Reduces Estradiol
por: Patrawala, Mahjabin, et al.
Publicado: (2023)

Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer
por: Pu, Shengyu, et al.
Publicado: (2022)

Weight Loss Intervention in Survivors of ER/PR-negative Breast Cancer
por: Vitolins, Mara Z, et al.
Publicado: (2014)

The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes
por: Parise, Carol A., et al.
Publicado: (2015)

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
por: Peláez-García, Alberto, et al.
Publicado: (2017)

Development of an Immune-Related Prognostic Signature in Breast Cancer
por: Xie, Peiling, et al.
Publicado: (2020)

The Diverse Distribution of Risk Factors between Breast Cancer Subtypes of ER, PR and HER2: A 10-Year Retrospective Multi-Center Study in China
por: Song, Qingkun, et al.
Publicado: (2013)

TIMAP Upregulation Correlates Negatively with Survival in HER2- Negative Subtypes of Breast Cancer
por: Obeidat, Marya, et al.
Publicado: (2021)

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
por: Dubsky, P., et al.
Publicado: (2013)

Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer
por: Bauer, Katrina, et al.
Publicado: (2010)

Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer
por: Liu, Xi-Yu, et al.
Publicado: (2018)

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
por: Buus, Richard, et al.
Publicado: (2018)

Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
por: Qing, Tao, et al.
Publicado: (2022)

Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date
por: Varella, Leticia, et al.
Publicado: (2023)

Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
por: Andrahennadi, Samitha, et al.
Publicado: (2021)

Expression of MTDH and IL-10 Is an Independent Predictor of Worse Prognosis in ER-Negative or PR-Negative Breast Cancer Patients
por: Chu, Pei-Yi, et al.
Publicado: (2020)

Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes
por: Utsumi, Toshiaki, et al.
Publicado: (2021)

Genetic and clinical landscape of ER + /PR- breast cancer in China
por: Dai, Danian, et al.
Publicado: (2023)

Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
por: Poorvu, Philip D., et al.
Publicado: (2020)

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
por: Ascione, Liliana, et al.
Publicado: (2022)

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
por: Rigter, L S, et al.
Publicado: (2013)

Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer
por: Kim, Yun Yeong, et al.
Publicado: (2018)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ryu, Ho Hyun, et al.
Publicado: (2021)

Immune Classification and Immune Landscape Analysis of Triple-Negative Breast Cancer
por: Hu, Shaojun, et al.
Publicado: (2021)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Ballinger, Tarah J., et al.
Publicado: (2018)

The integrative epigenomic-transcriptomic landscape of ER positive breast cancer
por: Gao, Yang, et al.
Publicado: (2015)

Targeting estrogen to kill ER-positive and ER-negative breast cancer
por: Jordan, VC
Publicado: (2005)

The nodal positivity rate in breast pCR patients with initially, clinically node-negative breast cancer after neoadjuvant systemic therapy: A systematic review and meta-analysis
por: Ma, Le, et al.
Publicado: (2023)

COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer
por: Glynn, Sharon A, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9i1l3c8igbt3r0kkkj4do09mk4